NanoHive’s Hive Standalone Cervical System received 510(k) clearance from the FDA in January 2023. Image Credit: Phonlamai Photo / Shutterstock.

US-based NanoHive Medical has closed $7m in Series C financing to develop and commercialise its 3D-printed titanium spinal interbody fusion devices.

The funds will be used to expand its US team, penetrate international markets, and expand the company’s strategic partnerships.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

NanoHive also plans to use the financing to expand its portfolio of soft titanium spinal interbody fusion devices “by way of product line extensions, product launches, and “smart” sensor implant delivery research and development”.

NanoHive’s soft titanium device portfolio consists of various spinal fusion devices. In January 2023, the US Food and Drug Administration (FDA) issued a 510(k) clearance for the Hive Standalone Cervical System. The implant system consists of a zero-profile design, interfixated with two self-tapping screws, as well as a cage and plate fixation option.

In April, NanoHive signed a supply schedule contract with the US Department of Veteran Affairs to supply its complete line of 3D-printed Hive interbody devices.

The spinal fusion orthopaedic device market is forecasted to grow over $8.9bn in 2030, as per a GlobalData market model. The interbody spinal fusion device segment will grow to roughly $4.2bn in 2030.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Multiple companies have used 3D printing technology to formulate spinal implants. 3D printing offers various advantages, including customisation, reduced production costs, and quick turnaround, all of which are expected to propel the medical 3D printing market to generate $4bn in 2026, as per GlobalData analysis.

In May 2023, Tissium raised €50m ($53.8m) in Series D financing to develop a 3D-printed implantable device and on-demand activated adhesive for suture-less nerve repair. In November 2023, Vy Spine’s ClariVy OsteoVy PEKK Cervical IBF device received clearance from the FDA. The device was made using 3D-printed Oxford Performance Materials’ OsteoFab technology in an OsteoVy lattice structure.